Nivolumab in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: Efficacy and Safety in CheckMate 141 by Prior Cetuximab Use.

Nivolumab in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: Efficacy and Safety in CheckMate 141 by Prior Cetuximab Use. Clin Cancer Res. 2019 09 01; 25(17):5221-5230.

View in: PubMed

subject areas

Adult
Aged
Aged, 80 and over
Antineoplastic Agents, Immunological
Cetuximab
ErbB Receptors
Head and Neck Neoplasms
Humans
Immunotherapy
Middle Aged
Neoplasm Metastasis
Neoplasm Recurrence, Local
Programmed Cell Death 1 Receptor
Survival Rate

authors with profiles

Everett E. Vokes